Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 11, 2016, Pages 2309-2317

  Jiang, Xue Mei ^a   Yu, Xiang Nan ^a,b   Huang, Ren Zheng ^b   Zhu, Hai Rong ^b   Chen, Xiao Peng ^a   Xiong, Ju ^c   Chen, Zheng Yi ^a   Huang, Xiao Xi ^a   Shen, Xi Zhong ^b,d   Zhu, Ji Min ^b  

^a HAIKOU PEOPLE S HOSPITAL   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^c PEOPLE S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Clinicopathological feature; Eukaryotic initiation factor 4E; Hepatocellular carcinoma; Prognostic biomarker; Tissue microarray

Indexed keywords

ALPHA FETOPROTEIN; INITIATION FACTOR 4E; EIF4ENIF1 PROTEIN, HUMAN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENCAPSULATION; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING; BIOSYNTHESIS; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR CELL LINE; TUMOR RECURRENCE; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; UP-REGULATION;

EID: 84986317442     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-016-2232-2     Document Type: Article

References (30)

1. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology (Baltimore, Md) 42:1208–1236. doi:10.1002/hep.20933
2. Campbell L, Jasani B, Griffiths DF, Gumbleton M (2015) Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma. Am J Cancer Res 5:2838–2848
3. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL (2000) Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 82:161–166. doi:10.1054/bjoc.1999.0894
4. Culjkovic B, Borden KL (2009) Understanding and targeting the eukaryotic translation initiation factor eif4e in head and neck cancer. J Oncol 2009:981679. doi:10.1155/2009/981679
5. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199. doi:10.1038/sj.onc.1207545
6. Diab-Assaf M et al (2015) Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis. Int J Clin Exp Pathol 8:404–413
7. Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474. doi:10.1245/s10434-010-0985-4
8. El-Serag HB (2011) Hepatocellular carcinoma. New Eng J Med 365:1118–1127. doi:10.1056/NEJMra1001683
9. Graff JR et al (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Investig 117:2638–2648. doi:10.1172/jci32044
10. Graff JR, Konicek BW, Carter JH, Marcusson EG (2008) Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68:631–634. doi:10.1158/0008-5472.can-07-5635
11. Graff JR et al (2009) eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 69:3866–3873. doi:10.1158/0008-5472.can-08-3472
12. Green AS et al (2012) The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. Br J Haematol 156:547–550. doi:10.1111/j.1365-2141.2011.08891.x
13. Heikkinen T et al (2013) Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment. Breast Cancer Res Treat 141:79–88. doi:10.1007/s10549-013-2671-2
14. Hu A, Sun M, Yan D, Chen K (2014) Clinical significance of mTOR and eIF4E expression in invasive ductal carcinoma. Tumori 100:541–546. doi:10.1700/1660.18176
15. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I (1994) Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106:720–727
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
17. Joshi B, Cameron A, Jagus R (2004) Characterization of mammalian eIF4E-family members. Eur J Biochem/FEBS 271:2189–2203. doi:10.1111/j.1432-1033.2004.04149.x
18. Ke AW et al (2009) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology (Baltimore, Md) 49:491–503. doi:10.1002/hep.22639
19. Khosravi S, Tam KJ, Ardekani GS, Martinka M, McElwee KJ, Ong CJ (2015) eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion. J Invest Dermatol 135:1358–1367. doi:10.1038/jid.2014.552
20. Nasr Z, Robert F, Porco JA Jr, Muller WJ, Pelletier J (2013) eIF4F suppression in breast cancer affects maintenance and progression. Oncogene 32:861–871. doi:10.1038/onc.2012.105
21. Nathan CO, Liu L, Li BD, Abreo FW, Nandy I, De Benedetti A (1997) Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 15:579–584. doi:10.1038/sj.onc.1201216
22. Niu Z et al (2014) Protein expression of eIF4E and integrin alphavbeta6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction. Cell Biosci 4:23. doi:10.1186/2045-3701-4-23
23. Osborne TS et al (2011) Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray. J Pediatr Hematol Oncol 33:524–528. doi:10.1097/MPH.0b013e318223d0c1
24. Pettersson F, Del Rincon SV, Miller WH Jr (2014) Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond. Exp Opin Ther Targets 18:1035–1048. doi:10.1517/14728222.2014.937426
25. Seki N et al (2010) Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma. Lung Cancer (Amsterdam, The Netherlands) 70:329–334. doi:10.1016/j.lungcan.2010.03.006
26. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81:814–821. doi:10.1038/sj.bjc.6690769
27. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. doi:10.3322/caac.21262
28. Wang XL, Cai HP, Ge JH, Su XF (2012) Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma. World J Gastroenterol 18:2540–2544. doi:10.3748/wjg.v18.i20.2540
29. Zhang P et al (2015) p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: a retrospective study. Oncol Lett 9:113–118. doi:10.3892/ol.2014.2631
30. Zhou FF et al (2011) Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol (Northwood, London, England) 28:1302–1307. doi:10.1007/s12032-010-9630-0